Polymorphisms in angiogenesis-related genes and prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 4, 2008, Pages 972-977

  Jacobs, Eric J ^a   Hsing, Ann W ^b   Bain, Elizabeth B ^a   Stevens, Victoria L ^a   Wang, Yiting ^a   Chen, Jinbo ^c   Chanock, Stephen J ^b   Zheng, S Lilly ^d   Xu, Jianfeng ^d   Thun, Michael J ^a   Calle, Eugenia E ^a   Rodriguez, Carmen ^a  

^a AMERICAN CANCER SOCIETY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERSTITIAL COLLAGENASE; LYMPHOTOXIN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER RISK; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOME; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS;

EID: 42149161082     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2787     Document Type: Article

References (27)

1. Folkman J, Kalluri R. Tumor Angiogenesis. In: Kufe DW, Pollock RE, Weischselbaum RR, et al., editors. Cancer Medicine 6. Hamilton (Ontario): BC Decker Inc; 2003. p. 161-94.
2. Nicholson B, Theodorescu D. Angiogenesis and prostate cancer growth. J Cell Biochem 2004;91:125-50.
3. Hrouda D, Nicol DL, Gardiner RA. The role of angiogenesis in prostate development and the pathogenesis of prostate cancer. Urol Res 2003;30:347-55.
4. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund S. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-94.
5. McCarron SL, Edwards S, Evans PR, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002;62:3369-72.
6. Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L. Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine 2006;35:21-8.
7. Kimbro KS, Simons JW. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 2006;13:739-49.
8. Chau CH, Permenter MG, Steinberg SM, et al. Polymorphism in the hypoxia-inducible factor 1α gene may confer susceptibility to androgen-independent prostate cancer. Cancer Biol Ther 2005;11:1222-5.
9. Fu XS, Choi E, Bubley GJ, Balk SP. Identification of hypoxia-inducible factor-1α (HIF-1α) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 2005;63:215-21.
10. Li H, Bubley GJ, Balk SP, et al. Hypoxia-inducible factor-1α (HIF-1α) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. Prostate 2007;67:1354-61.
11. Stolze IP, Tian YM, Appelhoff RJ, et al. Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional target genes. J Biol Chem 2004;279:42719-25.
12. Ravindranath N, Wion D, Brachet P, Djakiew D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 2001;22:432-43.
13. Araújo A, Ribeiro R, Azevedo I, et al. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist 2007;12:201-10
14. Ferrer FA, Miller LJ, Andrawis RI, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998;51:161-7.
15. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-α gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002;32:650-4.
16. Morbidelli L, Donnini S, Ziche M. Role of nitric oxide in the modulation of angiogenesis. Curr Pharm Des 2003;9:521-30.
17. Aaltoma SH, Lipponen PK, Kosma VM. Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res 2001;21:3101-6.
18. Medeiros R, Morais A, Vasconcelos A, et al. Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev 2002;11:343-50.
19. Medeiros RM, Morais A, Vasconcelos A, et al. Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7. Clin Cancer Res 2002;8:3433-7.
20. Yoon SO, Park SJ, Yun CH, Chung AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003;36:128-37.
21. Trudel D, Fradet Y, Meyer F, Harel F, Tetu B. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res 2003;63:8511-5.
22. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of SP1 in allele-specific transcriptional regulation. J Biol Chem 2001;276:7549-58.
23. Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort - rationale, study design and baseline characteristics. Cancer 2002;94:2490-501.
24. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
25. National Cancer Institute, NIH, DHHS. Cancer Genetic Markers of Susceptibility Study. [accessed 10 Oct 2007]. Available from: http://cgems.cancer.gov/data.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
27. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 2004;64:7622- 8.